CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor ...
Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...
Q3 2024 Earnings Call Transcript October 31, 2024 Madrigal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...
Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...
4d
Celebrations may be in order for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The ...
Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with ...
Celebrations may be in order for Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) shareholders, with the analysts... Madrigal Pharmaceuticals (MDGL) shares jumped after Novo Nordisk (NVO ...
6d
Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered ...
CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic ...
Sibold credited Rezdiffra's sales growth to the growing adoption of the treatment by prescribers, broader payer coverage for ...
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has reported its financial and operational achievements for the third quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback